 Meeting with FDA set for mid-2022 to discuss potential to begin pivotal trial using FT516 for patients with relapsedrefractory diffuse large B-cell lymphoma. If all goes well with FDA meeting for FT516, then a pivotal study should begin in the second half of 2022. 